Shouyan Deng, Yibo Zhang, Huanbin Wang, Wenhua Liang, Lu Xie, Ning Li, Yuan Fang, Yiting Wang, Jiayang Liu, Hao Chi, Yufan Sun, Rui Ye, Lishen Shan, Jiawei Shi, Zan Shen, Yonggang Wang, Shuhang Wang, Jean-Philippe Brosseau, Feng Wang, Grace Liu, Yingfei Quan, Jie Xu
Cancer immunotherapy has transformed treatment possibilities, but its effectiveness differs significantly among patients, indicating the presence of alternative pathways for immune evasion. Here, we show that ITPRIPL1 functions as an inhibitory ligand of CD3ε, and its expression inhibits T cells in the tumor microenvironment. The binding of ITPRIPL1 extracellular domain to CD3ε on T cells significantly decreased calcium influx and ZAP70 phosphorylation, impeding initial T cell activation...
April 5, 2024: Cell